Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology

Author(s): Romeo G. Mihăilă*

Volume 15, Issue 4, 2020

Page: [272 - 292] Pages: 21

DOI: 10.2174/1574892815666200925120717

Price: $65

Abstract

Background: The therapeutic outcomes and the prognosis of patients with various hematologic malignancies are not always ideal with the current standard of care.

Objective: The aim of this study is to analyze the results of the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates for the therapy of malignant hemopathies.

Methods: A mini-review was achieved using the articles published in Web of Science and PubMed between January 2017 and January 2020 and the new patents were made in this field.

Results: Naked monoclonal antibodies have improved the therapeutic results obtained with standard of care, but they also have side effects and the use of some of them can lead to the loss of the target antigen through trogocytosis, which explains the resistance that occurs during therapy. The results obtained with naked monoclonal antibodies have been improved by a better monoclonal antibody preparation, the use of bispecific antibodies (against two antigens on the target cell surface or by binding both surface antigen on target cells and T-cell receptor complex, followed by cytotoxic T-lymphocytes activation and subsequent cytolysis of the target cell), the use of monoclonal or bispecific constructs in frontline regimens, combining immunotherapy with chemotherapy, including through the use of antibody-drug conjugates (which provides a targeted release of a chemotherapeutic agent).

Conclusion: Immunotherapy and immuno-chemotherapy have improved the outcome of the patients with malignant hemopathies through a targeted, personalized therapy, with reduced systemic toxicity, which in some cases can even induce deep complete remissions, including minimal residual disease negativity.

Keywords: Antibody-drug conjugate, bispecific antibody, leukemia, lymphoma, monoclonal antibody, obinutuzumab, ofatumumab, rituximab.

« Previous Next »
[1]
Wei G, Wang J, Huang H, Zhao Y. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol 2017; 10(1): 150.
[http://dx.doi.org/10.1186/s13045-017-0516-x] [PMID: 28821272]
[2]
Golay J. Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias? J Autoimmun 2017; 85: 6-19.
[http://dx.doi.org/10.1016/j.jaut.2017.06.002] [PMID: 28666691]
[3]
Yeung CCS, Shadman M. How to choose the best treatment and testing for chronic lymphocytic leukemia in the tsunami of new treatment options. Curr Oncol Rep 2019; 21(8): 74.
[http://dx.doi.org/10.1007/s11912-019-0819-x] [PMID: 31327069]
[4]
Paul S, Rausch CR, Welch MA, Kantarjian HM, Jabbour EJ. SOHO state of the art update and next questions: Advances in the treatment of adult acute lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 2019; 19(8): 471-9.
[http://dx.doi.org/10.1016/j.clml.2019.06.011] [PMID: 31307896]
[5]
Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: Reactions to Taxanes and Monoclonal Antibodies. Clin Rev Allergy Immunol 2018; 54(3): 375-85.
[http://dx.doi.org/10.1007/s12016-016-8556-5] [PMID: 27277133]
[6]
Adem J, Eray M, Eeva J, Nuutinen U, Pelkonen J. Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas. Mol Immunol 2017; 88: 135-7.
[http://dx.doi.org/10.1016/j.molimm.2017.05.023] [PMID: 28644972]
[7]
Bobrowicz M, Dwojak M, Pyrzynska B, et al. HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 2017; 130(14): 1628-38.
[http://dx.doi.org/10.1182/blood-2016-08-736066] [PMID: 28830887]
[8]
Prica A, Crump M. Improving CD20 antibody therapy: Obinutuzumab in lymphoproliferative disorders. Leuk Lymphoma 2019; 60(3): 573-82.
[http://dx.doi.org/10.1080/10428194.2018.1498490] [PMID: 30668192]
[9]
Dinner S, Liedtke M. Antibody-based therapies in patients with acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2018; 2018(1): 9-15.
[http://dx.doi.org/10.1182/asheducation-2018.1.9] [PMID: 30504286]
[10]
Qin H, Wei G, Sakamaki I, et al. Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug-resistant human b-cell malignancies in vivo. Clin Cancer Res 2018; 24(5): 1114-23.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1193] [PMID: 29180606]
[11]
Zhang M, Wen B, Anton OM, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA 2018; 115(46): E10915-24.
[http://dx.doi.org/10.1073/pnas.1811615115] [PMID: 30373815]
[12]
Jiang B, Qi JY, Sun MY, et al. Tolerance and pharmacodynamics phase I clinical trial study of chimeric anti-CD20 monoclonal antibody IBI301 in Chinese patients with CD20-positive non-Hodgkin’s lymphoma. Zhonghua Xue Ye Xue Za Zhi 2018; 39(4): 320-4.
[PMID: 29779330]
[13]
Ohmachi K, Ogura M, Suehiro Y, et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int J Hematol 2019; 109(6): 657-64.
[http://dx.doi.org/10.1007/s12185-019-02635-9] [PMID: 30915717]
[14]
Watkins MP, Bartlett NL. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opin Investig Drugs 2018; 27(7): 601-11.
[http://dx.doi.org/10.1080/13543784.2018.1492549] [PMID: 29940805]
[15]
Lambert JM, Morris CQ. Antibody-Drug Conjugates (ADCs) for personalized treatment of solid tumors: A review. Adv Ther 2017; 34(5): 1015-35.
[http://dx.doi.org/10.1007/s12325-017-0519-6] [PMID: 28361465]
[16]
Li Z, Wang M, Yao X, et al. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment. Int Immunopharmacol 2018; 62: 299-308.
[http://dx.doi.org/10.1016/j.intimp.2018.06.034] [PMID: 30048860]
[17]
Horvat TZ, Seddon AN, Ogunniyi A, King AC, Buie LW, Daley RJ. The ABCs of immunotherapy for adult patients with B-Cell acute lymphoblastic leukemia. Ann Pharmacother 2018; 52(3): 268-76.
[http://dx.doi.org/10.1177/1060028017736539] [PMID: 29025266]
[18]
Rank CU, Stock W. Should immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol 2018; 31(4): 367-72.
[http://dx.doi.org/10.1016/j.beha.2018.09.015] [PMID: 30466749]
[19]
Valecha GK, Ibrahim U, Ghanem S, Asti D, Atallah JP, Terjanian T. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Rev Hematol 2017; 10(9): 783-99.
[http://dx.doi.org/10.1080/17474086.2017.1350165] [PMID: 28666090]
[20]
Jabbour E, Pui CH, Kantarjian H. Progress and innovations in the management of adult acute lymphoblastic leukemia. JAMA Oncol 2018; 4(10): 1413-20.
[http://dx.doi.org/10.1001/jamaoncol.2018.1915] [PMID: 29931220]
[21]
McDonald GB, Freston JW, Boyer JL, DeLeve LD. Liver complications following treatment of hematologic malignancy with anti-CD22-calicheamicin (Inotuzumab Ozogamicin). Hepatology 2019; 69(2): 831-44.
[http://dx.doi.org/10.1002/hep.30222] [PMID: 30120894]
[22]
Pirosa MC, Leotta S, Cupri A, et al. Long-Term Molecular remission achieved by antibody Anti-CD22 and ponatinib in a patient affected by Ph’+ acute lymphoblastic leukemia relapsed after second allogeneic hematopoietic stem cell transplantation: A Case Report. Chemotherapy 2018; 63(4): 220-4.
[http://dx.doi.org/10.1159/000492941] [PMID: 30372691]
[23]
Qi J, Chen SS, Chiorazzi N, Rader C. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. Methods 2019; 154: 70-6.
[http://dx.doi.org/10.1016/j.ymeth.2018.08.008] [PMID: 30145356]
[24]
Mikulska M, Lanini S, Gudiol C, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect 2018; 24(Suppl. 2): S71-82.
[http://dx.doi.org/10.1016/j.cmi.2018.02.003] [PMID: 29447988]
[25]
Skopelja-Gardner S, Jones JD, Hamilton BJ, Danilov AV, Rigby WFC. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells. J Immunol 2017; 199(4): 1275-82.
[http://dx.doi.org/10.4049/jimmunol.1602105] [PMID: 28710251]
[26]
Kater AP, van Oers MHJ, van Norden Y, et al. HOVON CLL study group. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica 2019; 104(1): 147-54.
[http://dx.doi.org/10.3324/haematol.2018.193854] [PMID: 30115656]
[27]
Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): Primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19(9): 1215-28.
[http://dx.doi.org/10.1016/S1470-2045(18)30414-5] [PMID: 30115596]
[28]
Rogers KA, Huang Y, Ruppert AS, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 2018; 132(15): 1568-72.
[http://dx.doi.org/10.1182/blood-2018-05-853564] [PMID: 30111609]
[29]
Qin Y, Song Y, Shen Z, et al. Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial. Cancer Commun (Lond) 2018; 38(1): 31.
[http://dx.doi.org/10.1186/s40880-018-0300-5] [PMID: 29843792]
[30]
Sawas A, Farber CM, Schreeder MT, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol 2017; 177(2): 243-53.
[http://dx.doi.org/10.1111/bjh.14534] [PMID: 28220479]
[31]
Zhai J, Qin Y, Zhu J, et al. Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas. Br J Clin Pharmacol 2017; 83(7): 1446-56.
[http://dx.doi.org/10.1111/bcp.13232] [PMID: 28072473]
[32]
Robak T, Warzocha K, Govind Babu K, et al. Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. Leuk Lymphoma 2017; 58(7): 1598-606.
[http://dx.doi.org/10.1080/10428194.2016.1253837] [PMID: 27830957]
[33]
Roswarski J, Roschewski M, Lucas A, et al. Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas. Leuk Lymphoma 2018; 59(6): 1466-9.
[http://dx.doi.org/10.1080/10428194.2017.1387908] [PMID: 29032710]
[34]
O’Mahony D, Morris JC, Stetler-Stevenson M, et al. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res 2009; 15(7): 2514-22.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-1254] [PMID: 19293260]
[35]
Assi R, Kantarjian H, Short NJ, et al. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk 2017; 17(12): 897-901.
[http://dx.doi.org/10.1016/j.clml.2017.08.101] [PMID: 28927784]
[36]
Yu Y, Li J, Zhu X, et al. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine 2017; 12: 1969-83.
[http://dx.doi.org/10.2147/IJN.S127575] [PMID: 28331319]
[37]
Huguet F, Tavitian S. Emerging biological therapies to treat acute lymphoblastic leukemia. Expert Opin Emerg Drugs 2017; 22(1): 107-21.
[http://dx.doi.org/10.1080/14728214.2016.1257606] [PMID: 27820973]
[38]
Zhang J, Shen D, Jia M, Zhao H, Tang Y. The targeting effect of Hm2E8b-NCTD-liposomes on B-lineage leukaemia stem cells is associated with the HLF-SLUG axis. J Drug Target 2018; 26(1): 55-65.
[http://dx.doi.org/10.1080/1061186X.2017.1339193] [PMID: 28627280]
[39]
Trnĕný M, Verhoef G, Dyer MJ, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica 2018; 103(8): 1351-8.
[http://dx.doi.org/10.3324/haematol.2017.168401] [PMID: 29748443]
[40]
Cherian S, Miller V, McCullouch V, Dougherty K, Fromm JR, Wood BL. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy. Cytometry B Clin Cytom 2018; 94(1): 112-20.
[http://dx.doi.org/10.1002/cyto.b.21482] [PMID: 27598971]
[41]
Tsang M, Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2017; 12(1): 29-38.
[http://dx.doi.org/10.1007/s11899-017-0366-1] [PMID: 28197963]
[42]
Coiffier B. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10. Expert Rev Clin Pharmacol 2017; 10(9): 923-33.
[http://dx.doi.org/10.1080/17512433.2017.1359537] [PMID: 28766389]
[43]
Babiker HM, Glode AE, Cooke LS, Mahadevan D. Ublituximab for the treatment of CD20 positive B-cell malignancies. Expert Opin Investig Drugs 2018; 27(4): 407-12.
[http://dx.doi.org/10.1080/13543784.2018.1459560] [PMID: 29609506]
[44]
Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. front oncol 2018; 8: 163.
[http://dx.doi.org/10.3389/fonc.2018.00163] [PMID: 29915719]
[45]
Davies A, Berge C, Boehnke A, et al. Subcutaneous rituximab for the treatment of B-Cell hematologic malignancies: A review of the scientific rationale and clinical development. adv ther 2017; 34(10): 2210-31.
[http://dx.doi.org/10.1007/s12325-017-0610-z] [PMID: 28983819]
[46]
Reagan PM, Friedberg JW. Reassessment of anti-CD20 therapy in lymphoid malignancies: impact, limitations, and new directions. Oncology (Williston Park) 2017; 31(5): 402-11.
[PMID: 28516439]
[47]
Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther 2017; 34(10): 2232-73.
[http://dx.doi.org/10.1007/s12325-017-0612-x] [PMID: 28983798]
[48]
Zoellner AK, Peter N, Zimmermann Y, Hutter G, Hiddemann W, Dreyling M. Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell line Eur J Haematol 2018.
[http://dx.doi.org/10.1111/ejh.13075.]
[49]
Jack J, Small GW, Brown CC, et al. Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance. Pharmacogenomics J 2018; 18(3): 467-73.
[http://dx.doi.org/10.1038/tpj.2017.41] [PMID: 29205205]
[50]
Wallner S, Gruber T, Baier G, Wolf D. Releasing the brake: Targeting Cbl-b to enhance lymphocyte effector functions. Clin Dev Immunol 2012; 2012: 692639.
[http://dx.doi.org/10.1155/2012/692639] [PMID: 22550535]
[51]
Esteban RE, Christianne B, Alvaro A, Demichelis-Gómez R. Prognostic effect of CD20 expression in adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2018; 18(5): 361-7.
[http://dx.doi.org/10.1016/j.clml.2018.02.013] [PMID: 29544762]
[52]
Levato L, Molica S. Rituximab in the management of acute lymphoblastic leukemia. Expert Opin Biol Ther 2018; 18(2): 221-6.
[http://dx.doi.org/10.1080/14712598.2018.1425389] [PMID: 29310477]
[53]
Nam J, Milenkovski R, Yunger S, Geirnaert M, Paulson K, Seftel M. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia. J Med Econ 2018; 21(1): 47-59.
[http://dx.doi.org/10.1080/13696998.2017.1372230] [PMID: 28837377]
[54]
Freise KJ, Jones AK, Menon RM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol 2017; 35(4): 679-84.
[http://dx.doi.org/10.1002/hon.2373] [PMID: 27982454]
[55]
Kreitman RJ. Hairy cell leukemia: Present and future directions. Leuk Lymphoma 2019; 60(12): 2869-79.
[http://dx.doi.org/10.1080/10428194.2019.1608536] [PMID: 31068044]
[56]
Falini B, Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 2019; 37(Suppl. 1): 30-7.
[http://dx.doi.org/10.1002/hon.2594] [PMID: 31187521]
[57]
Freeman CL, Sehn LH. A tale of two antibodies: Obinutuzumab versus rituximab. Br J Haematol 2018; 182(1): 29-45.
[http://dx.doi.org/10.1111/bjh.15232] [PMID: 29741753]
[58]
Hill SL, Davies A. Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Future Oncol 2018; 14(17): 1691-9.
[http://dx.doi.org/10.2217/fon-2017-0574] [PMID: 29405071]
[59]
Blair HA. GP2013: A Rituximab Biosimilar. BioDrugs 2017; 31(5): 465-8.
[http://dx.doi.org/10.1007/s40259-017-0245-2] [PMID: 28921160]
[60]
Deeks ED. CT-P10 (Truxima™): A Rituximab Biosimilar. BioDrugs 2017; 31(3): 275-8.
[http://dx.doi.org/10.1007/s40259-017-0226-5] [PMID: 28497220]
[61]
Singh SK, Pokalwar S, Bose S, Gupta S, Almal S, Ranbhor RS. Structural and functional comparability study of anti-CD20 monoclonal antibody with reference product. Biologics 2018; 12: 159-70.
[http://dx.doi.org/10.2147/BTT.S187744] [PMID: 30538425]
[62]
Abdollahpour-Alitappeh M, Hashemi Karouei SM, Lotfinia M, Amanzadeh A, Habibi-Anbouhi M. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line Artif Cells Nanomed Biotechnol 2018; 46(2): 1-8.
[http://dx.doi.org/10.1080/21691401.2018.1449119]
[63]
Cheadle EJ, Lipowska-Bhalla G, Dovedi SJ, et al. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia 2017; 31(7): 1611-21.
[http://dx.doi.org/10.1038/leu.2016.352] [PMID: 27890931]
[64]
Lunning M, Vose J, Nastoupil L, et al. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2019; 134(21): 1811-20.
[http://dx.doi.org/10.1182/blood.2019002118] [PMID: 31558467]
[65]
Yosifov DY, Wolf C, Stilgenbauer S, Mertens D. From Biology to Therapy: The CLL Success Story. HemaSphere 2019; 3(2): e175.
[http://dx.doi.org/10.1097/HS9.0000000000000175] [PMID: 31723816]
[66]
Klein C, Bacac M, Umana P, Fingerle-Rowson G. Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opin Investig Drugs 2017; 26(10): 1145-62.
[http://dx.doi.org/10.1080/13543784.2017.1373087] [PMID: 28845710]
[67]
Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 2017; 34(2): 324-56.
[http://dx.doi.org/10.1007/s12325-016-0451-1] [PMID: 28004361]
[68]
Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood 2017; 130(5): 581-9.
[http://dx.doi.org/10.1182/blood-2017-03-771832] [PMID: 28584136]
[69]
Soe ZN, Allsup D. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol 2017; 13(29): 2611-28.
[http://dx.doi.org/10.2217/fon-2017-0275] [PMID: 28850252]
[70]
Jewell RC, Kipps TJ, Dürig J, et al. Hx-CD20-407 Study Investigators. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma 2017; 58(2): 348-56.
[http://dx.doi.org/10.1080/10428194.2016.1195497] [PMID: 27389174]
[71]
Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw 2017; 15(3): 293-311.
[http://dx.doi.org/10.6004/jnccn.2017.0030] [PMID: 28275031]
[72]
Falchi L, Ferrajoli A, Jacobs I, Nava-Parada P. An evidence-based review of anti-CD20 antibody-containing regimens for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, or follicular lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18(8): 508-18.
[http://dx.doi.org/10.1016/j.clml.2018.05.009] [PMID: 29934061]
[73]
Palazzo A, Herter S, Grosmaire L, et al. The PI3Kδ-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in vivo. J Immunol 2018; 200(7): 2304-12.
[http://dx.doi.org/10.4049/jimmunol.1700323] [PMID: 29453281]
[74]
Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia 2019; 33(11): 2555-62.
[http://dx.doi.org/10.1038/s41375-019-0592-8] [PMID: 31591468]
[75]
García-Sanz R, Jiménez C, González De La Calle V, Sarasquete ME. A safety profile of medications used to treat Waldenström’s macroglobulinemia. Expert Opin Drug Saf 2018; 17(6): 609-21.
[http://dx.doi.org/10.1080/14740338.2018.1477936] [PMID: 29768934]
[76]
Weide R, Feiten S, Chakupurakal G, et al. Survival improvement of patients with Chronic Lymphocytic Leukemia (CLL) in routine care 1995-2017. Leuk Lymphoma 2020; 61(3): 557-66.
[http://dx.doi.org/10.1080/10428194.2019.1680840] [PMID: 31682164]
[77]
Yurkiewicz IR, Muffly L, Liedtke M. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Drug Des Devel Ther 2018; 12: 2293-300.
[http://dx.doi.org/10.2147/DDDT.S150317] [PMID: 30087554]
[78]
Lamb YN. Inotuzumab ozogamicin: First global approval. Drugs 2017; 77(14): 1603-10.
[http://dx.doi.org/10.1007/s40265-017-0802-5] [PMID: 28819740]
[79]
Kantarjian HM, Su Y, Jabbour EJ, et al. Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia. Cancer 2018; 124(10): 2151-60.
[http://dx.doi.org/10.1002/cncr.31317] [PMID: 29508899]
[80]
Choudhry A, O’Brien SM. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia. Drugs Today (Barc) 2017; 53(12): 653-65.
[http://dx.doi.org/10.1358/dot.2017.53.12.2737934] [PMID: 29517084]
[81]
Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2018; 19(2): 240-8.
[http://dx.doi.org/10.1016/S1470-2045(18)30011-1] [PMID: 29352703]
[82]
Dhillon S. moxetumomab pasudotox: first global approval. Drugs 2018; 78(16): 1763-7.
[http://dx.doi.org/10.1007/s40265-018-1000-9] [PMID: 30357593]
[83]
Lin AY, Dinner SN. Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval. Blood Adv 2019; 3(19): 2905-10.
[http://dx.doi.org/10.1182/bloodadvances.2019000507] [PMID: 31594764]
[84]
Müller F, Cunningham T, Stookey S, et al. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl Acad Sci USA 2018; 115(8): E1867-75.
[http://dx.doi.org/10.1073/pnas.1714512115] [PMID: 29432154]
[85]
Kinjyo I, Matlawska-Wasowska K, Chen X, et al. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 2017; 64(11)
[http://dx.doi.org/10.1002/pbc.26604] [PMID: 28449314]
[86]
Advani RH, Lebovic D, Chen A, et al. Phase I study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-hodgkin lymphoma. Clin Cancer Res 2017; 23(5): 1167-76.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0772] [PMID: 27601593]
[87]
Kraeber-Bodere F, Pallardy A, Maisonneuve H, et al. Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: A prospective, single group, phase 2 trial. Lancet Haematol 2017; 4(1): e35-45.
[http://dx.doi.org/10.1016/S2352-3026(16)30168-5] [PMID: 27964867]
[88]
Sheng L, Fu H, Tan Y, et al. Unusual expansion of CD3+CD56+ natural killer T-like cells in peripheral blood after anticytokine treatment for graft-versus-host disease: A case report. Medicine (Baltimore) 2018; 97(38): e12429.
[http://dx.doi.org/10.1097/MD.0000000000012429] [PMID: 30235723]
[89]
Galimberti S, Grassi S, Baratè C, et al. The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Front Oncol 2018; 8: 555.
[http://dx.doi.org/10.3389/fonc.2018.00555] [PMID: 30574454]
[90]
Nakashima M, Yamochi T, Watanabe M, et al. CD30 characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals. Clin Cancer Res 2018; 24(21): 5445-57.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-0268] [PMID: 30068708]
[91]
Bagot M. New targeted treatments for cutaneous T-cell lymphomas. Indian J Dermatol 2017; 62(2): 142-5.
[http://dx.doi.org/10.4103/ijd.IJD_73_17] [PMID: 28400633]
[92]
Bewersdorf JP, Stahl M, Zeidan AM. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Leuk Lymphoma 2019; 60(6): 1354-69.
[http://dx.doi.org/10.1080/10428194.2018.1546854] [PMID: 30652518]
[93]
Medeiros BC, Tanaka TN, Balaian L, et al. A phase I/II trial of the combination of azacitidine and gemtuzumab ozogamicin for treatment of relapsed acute myeloid leukemia. Clin Lymphoma Myeloma leuk 2018; 18(5): 346-52.
[http://dx.doi.org/10.1016/j.clml.2018.02.017] [PMID: 29572158]
[94]
Knepper TC, Saller J, Walko CM. Novel and expanded oncology drug approvals of 2016-PART 2: New options in the management of hematologic malignancies. Oncology (Williston Park) 2017; 31(2): 138-46.
[PMID: 28205194]
[95]
Russ A, Hua AB, Montfort WR, et al. Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. Blood Rev 2018; 32(6): 480-9.
[http://dx.doi.org/10.1016/j.blre.2018.04.005] [PMID: 29709247]
[96]
Valipour B, Abedelahi A, Naderali E, et al. Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. Life Sci 2020; 242: 117223.
[http://dx.doi.org/10.1016/j.lfs.2019.117223] [PMID: 31881222]
[97]
Suwabe T, Shibasaki Y, Kaihatsu A, et al. Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy. Rinsho Ketsueki 2017; 58(1): 32-6.
[PMID: 28190863]
[98]
Fuji S. Role of anti-CCR4 antibody in the treatment of transplant-eligible patients with aggressive adult T-cell leukemia/lymphoma. Rinsho Ketsueki 2018; 59(4): 426-31.
[PMID: 29743403]
[99]
Makita S, Tobinai K. Mogamulizumab for the treatment of T-cell lymphoma. Expert Opin Biol Ther 2017; 17(9): 1145-53.
[http://dx.doi.org/10.1080/14712598.2017.1347634] [PMID: 28649848]
[100]
Mohammed TO, Chagan-Yasutan H, Ashino Y, et al. Galectin-9 as a predictive marker for the onset of immune-related adverse effects associated with anti-CCR4 MoAb therapy in patients with adult T cell leukemia. Tohoku J Exp Med 2017; 241(3): 201-8.
[http://dx.doi.org/10.1620/tjem.241.201] [PMID: 28321034]
[101]
Shiratori S, Ohhigashi H, Ito S, et al. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma. Hematol Oncol 2017; 35(1): 138-40.
[http://dx.doi.org/10.1002/hon.2242] [PMID: 26177633]
[102]
Neiveyans M, Melhem R, Arnoult C, et al. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs 2019; 11(3): 593-605.
[http://dx.doi.org/10.1080/19420862.2018.1564510] [PMID: 30604643]
[103]
Okano F, Saito T, Ido T, Shimizu M. Pharmaceutical composition for treatment and prevention of cancer. US20110129478, 2011.
[104]
Leung S. Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof. US20160363597, 2016.
[105]
Staudt LM, Wright GW, Scott DW, et al. Method for subtyping lymphoma types by means of expression profiling. US20160283653, 2016.
[106]
West JW, Sagert JG, Hostetter DR, et al. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof. US20170002082, 2017.
[107]
Grogan J, Johnston RJ, Irving B, et al. Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors. US20170044256, 2017.
[108]
Markovic SN, Nevala WK. Methods of using albumin-CD20 paclitaxel nanoparticle complex compositions for treating cancer. US20170182185, 2017.
[109]
Kwakkenbos MJ, Wagner K, Bakker AQ. Means and methods for producing stable antibodies. US20170008952, 2017.
[110]
Dang L, Fantin V, Gross S, et al. Methods and compositions for cell-proliferation-related disorders. US20170325708, 2017.
[111]
Zupancic TJ, Kittle JD, Zeng L, Vedamoorthy S, Brody RS, Williams MR. Universal biosensor system for analyte detection. US20180180608, 2018.
[112]
Bilsborough JM. Methods of treating skin disorders using anti-IL-31RA antibodies. US20180244790, 2018.
[113]
Liu J, Ring AM, Volkmer JP, Weissman IL. Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRP.alpha. antibody therapy. US20180037652, 2018.
[114]
Ast O, Bacac M, Imhof-Jung S, et al. Bispecific T cell activating antigen binding molecules. US20180222981, 2018.
[115]
Shachar I, Binsky I, Marom A. Anti CD84 antibodies, compositions comprising same and uses thereof. US20180327493, 2018.
[116]
Bossenmaier B, Kettenberger H, Klein C, et al. Monovalent antigen binding proteins. US20180037633, 2018.
[117]
Lin K. Methods and compositions for detecting and treating drug resistant AKT mutant. US20180327860, 2018.
[118]
Fournier N, Fontayne A, Romeuf C. Anti-CD303 monoclonal antibodies. US20180086834, 2018.
[119]
Carrigan CN, Ab O, Tavares D, Wolf BB. Diagnostic assays and kits for detection of folate receptor. US20190227073, 2019.
[120]
Kuhn P, Kolatkar A, Kunken J, Marrinucci D, Yang X, Stuelpnagel JR. Method of using non-rare cells to detect rare cells. US20190257834, 2019.
[121]
Zhen H. ABCG2 monoclonal antibody and uses thereof. US20190248912, 2019.
[122]
Akle C, Grange J, Bilyard K. Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy. US20190008942, 2019.
[123]
Ptacin J, Caffaro CE, Milla M. Cytokine conjugates for the treatment of proliferative and infectious diseases. US20190314455, 2019.
[124]
Wendtner CM, Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma 2018; 59(2): 300-10.
[http://dx.doi.org/10.1080/10428194.2017.1330474] [PMID: 28565930]
[125]
Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother 2017; 18(9): 857-73.
[http://dx.doi.org/10.1080/14656566.2017.1324420] [PMID: 28446054]
[126]
Sanyal R, Polyak MJ, Zuccolo J, et al. MS4A4A: A novel cell surface marker for M2 macrophages and plasma cells. Immunol Cell Biol 2017; 95(7): 611-9.
[http://dx.doi.org/10.1038/icb.2017.18] [PMID: 28303902]
[127]
Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. FASEB J 2018; 32(9): 5063-77.
[http://dx.doi.org/10.1096/fj.201701544R] [PMID: 29913558]

Rights & Permissions Print Cite
Article Metrics
108
© 2024 Bentham Science Publishers | Privacy Policy